This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

L. Ann Tanner, RPh; L. A. Bosco, MD, MPH

Arch Intern Med. 1988;148(2):379-380.

Abstract
• Gynecomastia is a reaction that is not usually associated with calcium channel blocker therapy. The Division of Epidemiology and Surveillance, within the US Food and Drug Administration (Rockville, Md), has received 31 reports of gynecomastia occurring after the use of these drugs. The underlying mechanism of this reaction is unknown, although two patients did report elevated prolactin levels. Gynecomastia developed in two patients, resulting in the surgical removal of the breast and/or nodules before discontinuation of drug therapy. The possibility of an association between calcium channel blockers and gynecomastia should be considered before an extensive workup or surgical procedure is undertaken.

(Arch Intern Med 1988;148:379-380)

Author Affiliations
From the Division of Epidemiology and Surveillance, Office of Epidemiology and Biostatistics, Center for Drugs and Biologics, Food and Drug Administration, Rockville, Md.

Footnotes
Accepted for publication Oct 6, 1987.

The views expressed herein are those of the authors and are not to be construed as official, or as reflecting the views of the US Food and Drug Administration.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hypertension, Antihypertensive Therapy, and Erectile Dysfunction
Papatsoris and Korantzopoulos
ANGIOLOGY 2006;57:47-52.
ABSTRACT  

Unilateral Gynecomastia Induced by Treatment With Diltiazem
Otto and Richter
Arch Intern Med 1994;154:351-351.
ABSTRACT